KR980002051A - 실넨나필의 제조 방법 - Google Patents

실넨나필의 제조 방법 Download PDF

Info

Publication number
KR980002051A
KR980002051A KR1019970024457A KR19970024457A KR980002051A KR 980002051 A KR980002051 A KR 980002051A KR 1019970024457 A KR1019970024457 A KR 1019970024457A KR 19970024457 A KR19970024457 A KR 19970024457A KR 980002051 A KR980002051 A KR 980002051A
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
solvent
group
amine
Prior art date
Application number
KR1019970024457A
Other languages
English (en)
Other versions
KR100207352B1 (en
Inventor
피터 제임스 듄
앨버트 쇼 우드
Original Assignee
무어 제임스 더블유
화이자 리서치 앤드 디벨롭먼트 캄파니 엔브이/에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR980002051(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 무어 제임스 더블유, 화이자 리서치 앤드 디벨롭먼트 캄파니 엔브이/에스에이 filed Critical 무어 제임스 더블유
Publication of KR980002051A publication Critical patent/KR980002051A/ko
Application granted granted Critical
Publication of KR100207352B1 publication Critical patent/KR100207352B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

하기 화학식(2)의 화합물을 환화시킴을 포함하는 하기 화학식(1)의 화합물의 제조 방법.

Description

실넨나필의 제조 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (17)

  1. 하기 화학식(2)의 화합물을 염기성, 중성 또는 산성 조건하에서 환화시킴을 포함하는 화학식(1)의 화합물의 제조 방법 ;
  2. 제1항에 있어서, 염기의 존재하에, 바람직하게는 용매중에서, 선택적으로 과산화 수소 또는 과산화 염의 존재하에 환화시킨 후, 필요에 따라 혼합물을 중화시키는 방법.
  3. 제2항에 있어서, 염기가 C1-C12알칸올, C3-C12사이클로알칸올, (C3-C8사이클로알킬)C1-C6알칸올, 암모니아, C1-C12알킬아민, 디(C1-|12알킬)아민, C3-C8사이클로알킬아민, N-(C3-C8사이클로알킬)-N-(C1-C12알킬)아민, 디(C3-C8사이클로알킬)아민, (C3-C8사이클로알킬)C1-C6알킬아민, N-(C3-C8사이클로알킬)C|1-C6알킬-N-(C1-C12알킬)아민, N-(C3-C8사이클로알킬)C1-C6알킬-N-(C3-C8사이클로알킬)아민, 디[(C3-C8사이클로알킬)C1-C6알킬]아민의 금속 염, 및 이미다졸, 트리아졸, 피롤리딘, 피페리딘, 헵타메틸렌이민, 모르폴린, 티오모르폴린 및 1-(C1-C4알킬)피페라진으로 구성된 군에서 선택된 헤테로사이클 아민; 수소화 금속, 플루오르화 금속, 수산화 금속, 산화 금속, 탄산금속 및 중탄산 금속(이때, 금속은 리튬, 나트륨, 칼륨, 루비듐, 세슘, 베릴륨, 마그네슘, 칼슘, 스트론튬, 바륨, 알루미늄, 인듐, 탈륨, 티탄, 지르코늄, 코발트, 구리, 은, 아연, 카드뮴, 수은 및 세륨으로 구성된 군에서 선택된다); 및 C7-C12비사이클아미딘으로 구성된 군에서 선택되고 ; 용매가 C1-C12알칸올, C3-C12사이클로 알칸올, (C3-C8사이클로알킬)C1-C6알칸올, C3-C9알칸온, C4-C10사이클로알칸온, C5-C12알킬 에테르, 1,2-디메톡시에탄, 1,2-디에톡시에탄, 디글림, 테트라하이드로푸란, 1,4-디옥산, 벤젠, 톨루엔, 크실렌, 클로로벤젠, 디클로로벤젠, 아세토니트릴, 디메틸 설폭사이드, 설폴란, 디메틸포름아미드, 디메틸아세트아미드, N-메틸피롤리딘-2-온, 피롤리딘-2-온, 피리딘 및 물, 및 이들의 혼합물로 구성된 군에서 선택되는 방법.
  4. 제3항에 있어서, 염기가 C1-C12알칸올, C3-C12사이클로알칸올 및 (C3-C8사이클로알킬)C1-C6알칸올의 알칼리 또는 알칼리토 금속 염 ; 암모니아, N-(2차 또는 3차 C3-C6알킬)-N-(1차, 2차 또는 3차 C3-C6알킬)아민, C3-C|8사이클로알킬아민, N-(C3-C8사이클로알킬)-N-(1차, 2차 또는 3차 C3-C6알킬)아민, 디(C3-C8사이클로알킬)아민 및 1-메틸피페라진의 알칼리 금속 염; 및 수소화 알칼리 또는 알칼리토 금속, 수산화 알칼리 또는 알칼리토 금속, 산화 알칼리 또는 알칼리토 금속, 탄산 알칼리 또는 알칼리토 금속 및 중탄산 알칼리 또는 알칼리토 금속; 1,5-디아자비사이클로[4.3.0]논-5-엔 및 1,8-디다자비사이클로[5.4.0]운데스-7-엔으로 구성된 군에서 선택되고 ; 용매가 에탄올, 2-프로판올, 2차 또는 3차 C4-C12알칸올, C3-C12사이클로알칸올, 3차 C4-C12사이클로알칸올, 2차 또는 3차(C3-C7사이클로알킬)C2-C6알칸올, C3-C9알칸온, 1,2-디메톡시에탄, 1,2-디에톡시에탄, 디글림, 테트라하디로푸란, 1,4-디옥산, 톨루엔, 크실렌, 클로로벤젠, 1,2-디클로로벤젠, 아세토니트릴, 디메틸 설폭사이드, 설폴란, 디메틸포름아미드, N-메틸피롤리딘-2-온, 피리딘 및 물, 및 이들의 혼합물로 구성된 군에서 선택되는 방법.
  5. 제2항 내지 제4항 중 어느 한 항에 있어서, 반응이 3 내지 170시간동안 50 내지 170℃에서 수행되는 방법.
  6. 제5항에 있어서, 사용되는 염기의 양이 약 1.0 내지 5.0몰 당량인 방법.
  7. 제6항에 있어서, 염기가 C1-C12알칸올, C4-C12사이클로알칸올, 암모니아, 사이클로헥실아민 및 1-메틸피페라진의 리튬, 나트륨 및 칼륨 염 ; 수소화 리튬, 수소화 나트륨 및 수소화 칼륨; 탄산 세슘; 및 산화바륨으로 구성된 군에서 선택되고; 용매가 에탄올, 3차 C4-C10알콜, 3차 C6-C8사이클로알칸올, 테트라하이드로푸란, 1,4-디옥산 및 아세토니트릴로 구성된 군에서 선택되고, 반응은 60 내지 105℃에서 수행되고 사용된 염기의 양은 1.1 내지 2.0몰 당량인 방법.
  8. 제7항에 있어서, 염기가 C1-C12알콕사이드 및 수소화 리튬, 수소화 나트륨, 수소화 칼륨, 소다미드, 나트륨 사이클로헥실아미드 및 탄산 세슘으로 구성된 군에서 선택되고; 용매가 에탄올, t-부탄올, t-아밀 알콜, 1-메틸사이클로헥산올, 테트라하이드로푸란 및 1,4-디옥산으로 구성된 군에서 선택되고; 반응이 3 내지 60시간동안 수행되는 방법.
  9. 제8항에 있어서, 염기가 나트륨 에톡사이드, 나트륨 t-부톡사이드, 칼륨 t-부톡사이드 및 수소화 나트륨으로 구성된 군에서 선택되고; 용매가 에탄올, t-부탄올, t-아밀 알콜 및 테트라하이드로푸란으로 구성된 군에서 선택되는 방법.
  10. 제1항에 있어서, 화학식(2)의 화합물을 선택적으로 용매의 존재하 및/또는 선택적으로 탈수제 및/또는 기계적 물-제거 시스템의 존재하에서 환화시키는 방법.
  11. 제10항에 있어서, 용매가 1,2-디클로로벤젠, 디메틸 설폭사이드, 설폴란, N-메틸피롤리딘-2-온 및 피롤리딘-2-온 및 이들의 혼합물로 구성된 군에서 선택되고; 탈수제가 무수 탄산 칼륨, 무수 탄산 나트륨, 무수 황산 나트륨, 무수 황산 마그네슘, 오산화인 분자시브로 구성된 군에서 선택되는 방법.
  12. 제11항에 있어서, 용매가 1,2-디클로로벤젠, 설폴란 또는 N-메틸피롤리딘-2-온이고; 탈수제가 분자시브이고; 반응이 180 내지 220℃에서 0.5 내지 72시간동안 수행되는 방법.
  13. 제1항에 있어서, 선택적으로 용매의 존재하에서 양성자산 또는 루이스산의 존재중에 환화되는 방법.
  14. 제13항에 있어서, 양성자 산이 무기산, 오가노-설폰산, 오가노-인산 및 오가노-카복실산으로 구성된 군에서 선택되고; 루이스 산이 삼플루오르화 붕소, 삼염화 붕소, 삼브롬화 붕소, 염화 알루미늄, 브롬화 알루미늄, 사염화 규소, 사브롬화 규소, 염화 주석, 브롬화 주석, 오염화 인, 오브롬화 인, 사플루오르화 티탄, 사염화 티탄, 사브롬화 티탄, 염화 제2철, 플루오르화 아연, 염화 아연, 브롬화 아연, 요오드화 아연, 염화 수은, 브롬화 수은 및 요오드화 수은으로 구성된 군에서 선택되고; 용매가 C5-C12알칸, C5-C8사이클로알칸, C1-C12알칸산, C1-C4알칸올, C3-C9알칸온, C5-C12알킬 에테르, 1,2-디메톡시에탄, 1,2-디에톡시에탄, 디글림, 테트라히드로푸란, 1,4-디옥산, 벤젠, 톨루엔, 크실렌, 클로로벤젠, 디클로로벤젠, 니트로벤젠, 디클로로메탄, 디브로모메탄, 1,2-디클로로에탄, 아세토니트릴, 디메틸 설폭사이드, 설폴란, 디메틸 포름아미드, 디메틸아세트아미드, N-메틸피롤리딘-2-온 및 피롤리딘-2-온 및 이들의 혼합물로 구성된 군에서 선택되는 방법.
  15. 제14항에 있어서, 양성자 산이 농축 황산, 인산 또는 p-톨루엔설폰산이고; 루이스산이 삼플루오르화붕소, 염화 알루미늄, 사염화 규소, 염화 주석, 사염화 티탄, 염화 제2철 또는 염화 아연이고; 용매가 빙초산, 테트라하이드로푸란, 1,4-디옥산 또는 클로로벤젠이고 ; 반응이 65 내지 210℃에서 6 내지 300시간동안 수행되는 방법.
  16. 하기 화학식(2)의 화합물 :
  17. 하기 화학식(3)의 화합물 또는 그의 염산-트리에틸아민 이중염, 또는 그의 C1-C4알킬 에스테르 :
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970024457A 1996-06-14 1997-06-13 Process for preparing sildenafil KR100207352B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9612514.1 1996-06-14
GBGB9612514.1A GB9612514D0 (en) 1996-06-14 1996-06-14 Novel process

Publications (2)

Publication Number Publication Date
KR980002051A true KR980002051A (ko) 1998-03-30
KR100207352B1 KR100207352B1 (en) 1999-07-15

Family

ID=10795332

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970024457A KR100207352B1 (en) 1996-06-14 1997-06-13 Process for preparing sildenafil

Country Status (48)

Country Link
US (2) US5955611A (ko)
EP (2) EP0812845B1 (ko)
JP (2) JP2866841B2 (ko)
KR (1) KR100207352B1 (ko)
CN (2) CN1106399C (ko)
AP (1) AP717A (ko)
AR (1) AR003401A1 (ko)
AT (2) ATE246194T1 (ko)
AU (1) AU697684B2 (ko)
BG (1) BG62554B1 (ko)
BR (1) BR9703580A (ko)
CA (1) CA2207694C (ko)
CO (1) CO4780028A1 (ko)
CZ (1) CZ290942B6 (ko)
DE (2) DE69723846T2 (ko)
DK (2) DK0812845T3 (ko)
DZ (1) DZ2247A1 (ko)
EA (1) EA000102B1 (ko)
EG (1) EG24123A (ko)
ES (2) ES2201397T3 (ko)
GB (1) GB9612514D0 (ko)
GR (1) GR3031087T3 (ko)
HK (1) HK1033459A1 (ko)
HN (1) HN1997000072A (ko)
HR (1) HRP970326B1 (ko)
HU (1) HU224497B1 (ko)
ID (1) ID18745A (ko)
IL (3) IL125411A (ko)
IN (5) IN187350B (ko)
IS (2) IS1922B (ko)
MA (1) MA24205A1 (ko)
MX (1) MX9704433A (ko)
NO (2) NO304551B1 (ko)
NZ (1) NZ328084A (ko)
OA (1) OA10426A (ko)
PE (2) PE1299A1 (ko)
PL (1) PL189333B1 (ko)
PT (1) PT916675E (ko)
RS (2) RS49653B (ko)
SA (1) SA97180124B1 (ko)
SG (1) SG50024A1 (ko)
SI (2) SI0812845T1 (ko)
SK (5) SK283895B6 (ko)
TN (1) TNSN97102A1 (ko)
TR (1) TR199700470A2 (ko)
UA (1) UA27085C2 (ko)
UY (2) UY24585A1 (ko)
ZA (1) ZA975259B (ko)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
CN1281588C (zh) 1997-04-25 2006-10-25 美国辉瑞有限公司 制备吡唑并嘧啶酮类化合物的新型中间体
EP0992240A4 (en) * 1997-05-29 2003-04-16 Mochida Pharm Co Ltd THERAPEUTIC AGENT FOR TREATING ANERECTION
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
CN100430396C (zh) 1997-11-12 2008-11-05 拜耳医药保健股份公司 用作磷酸二酯酶抑制剂的2-苯基取代的咪唑并三嗪酮
US6251904B1 (en) * 1998-04-20 2001-06-26 Pfizer Inc. Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
ES2220109T3 (es) * 1998-09-04 2004-12-01 Ortho-Mcneil Pharmaceutical, Inc. 5-heterociclilpirazolo (4,3-d) pirimidin-7-onas para el tratamiento de la disfuncion erectil masculina.
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
WO2000078760A1 (fr) * 1999-06-21 2000-12-28 The Biochemical Pharmaceutical Factory Of Zhuhai Sez Procede de preparation de sildenafil, agent et procede d'obtention d'un comprime mixte a base de sildenafil et de chlorhydrate d'apomorphine
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
WO2001019827A1 (en) * 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
EA200200240A1 (ru) 1999-10-11 2002-10-31 Пфайзер Инк. 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
YU84702A (sh) * 2000-06-22 2005-09-19 Pfizer Inc. Novi postupak za pripremanje pirazolopirimidinona
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6730786B2 (en) * 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
YU51701A (sh) * 2000-07-28 2003-12-31 Pfizer Inc. Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
CA2457944C (en) * 2001-08-28 2009-09-29 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
WO2005067936A2 (en) * 2004-01-05 2005-07-28 Teva Pharmaceutical Industries Ltd. Methods for the production of sildenafil base and citrate salt
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2008074194A1 (fr) * 2006-12-21 2008-06-26 Topharman Shanghai Co., Ltd. Procédé de préparation du sildénafil et de ses intermédiaires
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
BRPI0823356A2 (pt) 2008-12-12 2015-06-16 Rhein Siegfried Sa De Cv Composição de liberação pulsátil de sildenafil e processo para prepará-la
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CN102993205B (zh) * 2012-12-27 2015-04-15 华润赛科药业有限责任公司 一种高收率制备高纯度西地那非游离碱的纯化方法
CN103044330B (zh) * 2013-01-14 2018-11-13 常州亚邦制药有限公司 西地那非中间体4-氨基-1-甲基-3-正丙基吡唑-5-甲酰胺的绿色合成新工艺
CN105085526B (zh) * 2014-05-15 2017-08-01 重庆圣华曦药业股份有限公司 一种改进的西地那非制备方法
CN105753870B (zh) * 2016-04-01 2018-05-22 重庆康刻尔制药有限公司 一种西地那非杂质f及其制备方法和应用
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105837578A (zh) * 2016-04-05 2016-08-10 重庆康刻尔制药有限公司 一种西地那非杂质d的合成方法
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN112961160A (zh) * 2021-03-05 2021-06-15 遂成药业股份有限公司 一种西地那非的改良合成工艺
CN113754612B (zh) * 2021-10-26 2023-09-26 山东安舜制药有限公司 一种西地那非中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) * 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
CN1281588C (zh) * 1997-04-25 2006-10-25 美国辉瑞有限公司 制备吡唑并嘧啶酮类化合物的新型中间体
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
GB9612514D0 (en) 1996-08-14
TNSN97102A1 (fr) 2005-03-15
IN187319B (ko) 2002-03-23
PT916675E (pt) 2003-11-28
ES2201397T3 (es) 2004-03-16
SK283895B6 (sk) 2004-04-06
TR199700470A2 (xx) 1998-01-21
IL121000A0 (en) 1997-11-20
IS1923B (is) 2004-03-15
IN187320B (ko) 2002-03-23
HN1997000072A (es) 1997-12-26
ZA975259B (en) 1997-12-15
CO4780028A1 (es) 1999-05-26
HRP970326A2 (en) 1998-06-30
IL121000A (en) 2000-02-29
SI0916675T1 (en) 2003-12-31
US5955611A (en) 1999-09-21
NZ328084A (en) 1998-08-26
IN187350B (ko) 2002-03-30
SK283893B6 (sk) 2004-04-06
HU9701048D0 (en) 1997-08-28
IN187317B (ko) 2002-03-23
EP0812845B1 (en) 1999-07-14
AP717A (en) 1999-01-04
BR9703580A (pt) 1998-11-10
CZ290942B6 (cs) 2002-11-13
US6066735A (en) 2000-05-23
HRP970326B1 (en) 2000-10-31
KR100207352B1 (en) 1999-07-15
PL189333B1 (pl) 2005-07-29
IL125411A0 (en) 1999-03-12
IL125411A (en) 2000-02-29
UY24612A1 (es) 2000-09-29
EA199700061A1 (ru) 1997-12-30
UY24585A1 (es) 1997-12-02
ATE182150T1 (de) 1999-07-15
ATE246194T1 (de) 2003-08-15
NO972481L (no) 1997-12-15
SI0812845T1 (en) 1999-12-31
EA000102B1 (ru) 1998-08-27
PE1299A1 (es) 1999-01-13
IS4503A (is) 1997-12-15
CA2207694C (en) 1999-11-23
HU224497B1 (hu) 2005-10-28
CA2207694A1 (en) 1997-12-14
IS6634A (is) 2002-11-25
SA97180124A (ar) 2005-12-03
AU2487897A (en) 1997-12-18
DZ2247A1 (fr) 2002-12-18
NO306115B1 (no) 1999-09-20
NO304551B1 (no) 1999-01-11
JP3058863B2 (ja) 2000-07-04
PL320555A1 (en) 1997-12-22
HUP9701048A2 (hu) 1998-12-28
BG101569A (en) 1998-01-30
AU697684B2 (en) 1998-10-15
SA97180124B1 (ar) 2006-02-08
MX9704433A (es) 1998-11-30
CZ181197A3 (cs) 1998-03-18
SG50024A1 (en) 1998-06-15
EP0812845A1 (en) 1997-12-17
CN1282740A (zh) 2001-02-07
DE69723846T2 (de) 2004-03-04
DE69723846D1 (de) 2003-09-04
EP0916675A3 (en) 1999-07-14
SK283894B6 (sk) 2004-04-06
YU25497A (sh) 1998-12-23
SK283897B6 (sk) 2004-04-06
HK1033459A1 (en) 2001-08-31
NO972481D0 (no) 1997-05-30
RS20060484A (en) 2007-04-10
CN1149206C (zh) 2004-05-12
RS49924B (sr) 2008-09-29
DE69700321D1 (de) 1999-08-19
UA27085C2 (uk) 2000-02-28
IN187318B (ko) 2002-03-23
JP2866841B2 (ja) 1999-03-08
IS1922B (is) 2004-03-15
SK74397A3 (en) 1998-06-03
JPH1081688A (ja) 1998-03-31
EP0916675A2 (en) 1999-05-19
GR3031087T3 (en) 1999-12-31
NO985064L (no) 1997-12-15
SK283896B6 (sk) 2004-04-06
CN1168376A (zh) 1997-12-24
NO985064D0 (no) 1998-10-30
AP9701009A0 (en) 1997-07-31
ID18745A (id) 1998-05-07
DE69700321T2 (de) 1999-11-04
BG62554B1 (bg) 2000-02-29
EG24123A (en) 2008-07-06
ES2134051T3 (es) 1999-09-16
OA10426A (en) 2001-12-07
JPH11171879A (ja) 1999-06-29
EP0916675B1 (en) 2003-07-30
DK0916675T3 (da) 2003-10-27
MA24205A1 (fr) 1997-12-31
AR003401A1 (es) 1998-08-05
HUP9701048A3 (en) 2000-10-30
RS49653B (sr) 2007-09-21
CN1106399C (zh) 2003-04-23
DK0812845T3 (da) 1999-11-29
PE20011303A1 (es) 2001-12-25

Similar Documents

Publication Publication Date Title
KR980002051A (ko) 실넨나필의 제조 방법
IL165503A0 (en) Method for preparing fused oxazinones from ortho-amino aromatic carboxylic acid and a carboxylic acid in the presence of a sulfonyl chloride and pyridine
AR035663A1 (es) Clorhidrato de 2-butil-3-(4-[3-(dibutilamino)propoxi]benzoil)-5-nitro-benzofurano, procedimiento para su preparacion, y procedimiento de preparacion de 2-butil-3-(4-[3-(dibutilamino)propoxi]benzoil)-5-nitro-benzofurano
AU1442297A (en) Piperidone tachykinin antagonists
US3991103A (en) 5H Dibenzo (a,d) cycloheptene, 10,11 dihydro, 5(1-halo-3-dimethylaminoprop-1-ylidene) derivatives
ES2079517T3 (es) Procedimiento para la obtencion de bencilcetonas.
KR840004435A (ko) 페니실란산 1,1-디옥시드 및 그 유도체류의 제조방법
NO750341L (ko)
GB1022940A (en) Novel substituted quinolines and method of preparing the same
FI932126A0 (fi) Foerfarande foer framstaellning av 2-klor-5-klormetylpyridin
CN1152018C (zh) 1，3－二苄基咪唑啉－2－酮－顺－4，5－二羧酸（i）的制备方法
RU2002122754A (ru) Способ получения хинолилакрилонитрила и соответствующих промежуточных продуктов
ELDERFIELD et al. THE VON BRAUN CYANOGEN BROMIDE REACTION. II. APPLICATION TO N-ARYLPYRROLIDINES1, 2
NO177748B (no) Fremgangsmåte for å redusere en karbonylinneholdende acridin
Anderson et al. Synthesis of 4‐(2‐chloroethyl)‐2, 3‐dihydro [1, 4] oxazino [2, 3‐b] quinoline and 4‐(2‐chloroethyl) 2, 3‐dihydropyrido [2, 3‐b][1, 4] oxazine
NO144069B (no) Difluorbutyrofenonderivater som er anvendelige for fremstilling av terapeutisk aktive butyrofenonderivater
IE43620L (en) N-aralkyl-2-amino-propanamides, antidepressants
PL364001A1 (en) Method for fluoromethylation of alcohols via halogenative decarboxylation
Dygos The synthesis of syn‐and anti‐11‐hydroxy‐12‐methyl‐10, 11‐dihydro‐5, 10‐imino [5H] dibenzo [a, d] cycloheptene
JPH0426659A (ja) 含フッ素ｎ，ｎ，ｎ’，ｎ’―テトラアリールベンジジン誘導体およびその製造方法
NO943861L (no) Trisyklisk forbindelse til bruk som tachykinin-antagonist
Deruiter et al. Investigation of the synthesis and analgesic activity of 1‐substituted 4‐(propananilido) perhydroazepines
US3261839A (en) Ethynylated quinolizines
PL195166B1 (pl) Sposób wytwarzania N-[5-(difenylofosfinoilometylo)-4-(4-fluorofenylo)-6-izopropylopirymidyn-2-ylo]-N-metylometanosulfonamidu
ZA837500B (en) Benzothiazine compounds,processes for preparing them and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120329

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee